COMEBACK OF THE YEAR Robinhood’s profit surge reclaims the spotlight NYSE - Delayed Quote • USD ResMed Inc. (RMD) Follow Compare 230.21 -12.41 (-5.11%) At close: December 18 at 4:00:02 PM EST 230.22 +0.01 (+0.00%) Pre-Market: 7:35:16 AM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing The blood testing process integrating BD's MiniDraw System with Babson's BetterWay technologies is likely to lower common barriers to testing and improve patient outcomes. With 74% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns Key Insights Given the large stake in the stock by institutions, ResMed's stock price might be vulnerable to their... SNN Stock Might Rise Following FDA Nod for AETOS Stemless Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty. ZBH Stock Might Rise Following FDA Nod for OsseoFit Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025. We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story... Why ResMed (RMD) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Zacks.com featured highlights include InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands have been highlighted in this Screen of The Week article. RMD or PODD: Which Is the Better Value Stock Right Now? RMD vs. PODD: Which Stock Is the Better Value Option? 5 Solid Dividend Growth Stocks to Buy Now InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands seem excellent choices for your portfolio. QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments. Scoop Up These 3 GARP Stocks to Receive Handsome Returns The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RMD, OUT and CTAS are some stocks that hold promise. Returns on Capital Paint A Bright Future For ResMed (NYSE:RMD) If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for... Here is Why Growth Investors Should Buy ResMed (RMD) Now ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials. Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Cooper Companies Q4 Earnings Beat, Revenues Miss, Stock Falls COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well. ResMed (RMD) Rose 15% in Q3 Fidelity Investments, an investment management company, recently released its “Fidelity Growth Strategies Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. Fidelity Growth Strategies Fund is a diversified domestic equity strategy with a focus on mid-cap growth. the fund’s Retail Class shares gained 6.28% in the third quarter, modestly […] PDCO Stock Gains Despite Q2 Earnings Miss and Lower Margins Patterson Companies' overall topline in the second quarter of fiscal 2025 benefits from strength in its Animal Health segment. ZBH Stock Might Rise Following FDA Nod for Knee Implant Component Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025. Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios ResMed, Haemonetics, Phibro and Agios have been highlighted in this Industry Outlook article. Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS? Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.